ALT

alanine aminotransferase

ARFI

acoustic radiation force impulse

APRI

aspartate aminotransferase to platelet ratio index

ART

antiretroviral treatment

AST

aspartate aminotransferase

CSPH

clinically significant portal hypertension

DAA

direct-acting antiviral

eGFR

estimated glomerular filtration rate

ELF

Enhanced Liver Fibrosis

ESRD

FCH

fibrosing cholestatic hepatitis

FIB-4

Fibrosis-4

GRADE

Grading of Recommendations Assessment, Development and Evaluation

Gt

genotype

HAV

hepatitis A virus

HBV

hepatitis B virus

HCC

hepatocellular carcinoma

HCV

hepatitis C virus

HIV

human immunodeficiency virus

IFN

Interferon

INR

international normalised ratio

LFT

liver function test

LSM

liver stiffness measurement

MSM

men who have sex with men

MELD

Model for End-Stage Liver Disease

mTOR

mammalian target of rapamycin

NSBB

non-selective beta-blocker

PBAC

Pharmaceutical Benefits Advisory Committee

PBS

Pharmaceutical Benefits Scheme

PCR

polymerase chain reaction

pegIFN

peginterferon-alfa

PWID

people who inject drugs

RAS

resistance-associated substitution

HSD

Highly Specialised Drugs

SVR

sustained virological response at 12 weeks after treatment (cure)

TAF

tenofovir alafenamide

TDF

tenofovir disoproxil fumarate

TGA

Therapeutic Goods Administration

ULN

upper limit of normal